269 related articles for article (PubMed ID: 9407971)
1. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53-induced immortalization of primary human mammary epithelial cells.
Gao Q; Hauser SH; Liu XL; Wazer DE; Madoc-Jones H; Band V
Cancer Res; 1996 Jul; 56(13):3129-33. PubMed ID: 8674072
[TBL] [Abstract][Full Text] [Related]
3. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
4. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his).
Gollahon LS; Shay JW
Oncogene; 1996 Feb; 12(4):715-25. PubMed ID: 8632893
[TBL] [Abstract][Full Text] [Related]
5. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells.
Yang G; Rosen DG; Mercado-Uribe I; Colacino JA; Mills GB; Bast RC; Zhou C; Liu J
Carcinogenesis; 2007 Jan; 28(1):174-82. PubMed ID: 16829690
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
8. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells.
Dimri GP; Martinez JL; Jacobs JJ; Keblusek P; Itahana K; Van Lohuizen M; Campisi J; Wazer DE; Band V
Cancer Res; 2002 Aug; 62(16):4736-45. PubMed ID: 12183433
[TBL] [Abstract][Full Text] [Related]
9. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
11. High susceptibility of a human breast epithelial cell type with stem cell characteristics to telomerase activation and immortalization.
Sun W; Kang KS; Morita I; Trosko JE; Chang CC
Cancer Res; 1999 Dec; 59(24):6118-23. PubMed ID: 10626801
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of p53 mutants on the growth of human bronchial epithelial cells.
Coursen JD; Bennett WP; Khan MA; Forrester K; Pietenpol JA; Harris CC
Mol Carcinog; 1997 Jul; 19(3):191-203. PubMed ID: 9254886
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.
Katayose D; Gudas J; Nguyen H; Srivastava S; Cowan KH; Seth P
Clin Cancer Res; 1995 Aug; 1(8):889-97. PubMed ID: 9816059
[TBL] [Abstract][Full Text] [Related]
14. Events in the immortalizing process of primary human mammary epithelial cells by the catalytic subunit of human telomerase.
Kim H; Farris J; Christman SA; Kong BW; Foster LK; O'Grady SM; Foster DN
Biochem J; 2002 Aug; 365(Pt 3):765-72. PubMed ID: 11978176
[TBL] [Abstract][Full Text] [Related]
15. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
16. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line.
DiRenzo J; Signoretti S; Nakamura N; Rivera-Gonzalez R; Sellers W; Loda M; Brown M
Cancer Res; 2002 Jan; 62(1):89-98. PubMed ID: 11782364
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation.
Chhipa RR; Kumari R; Upadhyay AK; Bhat MK
Exp Cell Res; 2007 Nov; 313(19):3945-58. PubMed ID: 17935714
[TBL] [Abstract][Full Text] [Related]
18. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
19. Modulation of gene expression by tumor-derived p53 mutants.
Scian MJ; Stagliano KE; Ellis MA; Hassan S; Bowman M; Miles MF; Deb SP; Deb S
Cancer Res; 2004 Oct; 64(20):7447-54. PubMed ID: 15492269
[TBL] [Abstract][Full Text] [Related]
20. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.
Zhou X; Wang XW; Xu L; Hagiwara K; Nagashima M; Wolkowicz R; Zurer I; Rotter V; Harris CC
Cancer Res; 1999 Feb; 59(4):843-8. PubMed ID: 10029073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
